Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Bioorg Khim ; 37(2): 216-22, 2011.
Article in Russian | MEDLINE | ID: mdl-21721254

ABSTRACT

L-[methyl-(11C)]-methionine ([11C]MET), labelled with carbon-11 (T1/2 = 20 min), is the most commonly used amino acid radiotracer for PET diagnostics of brain tumors. The production of [11C]MET via on-line 11C-methylation of L-homocysteine thiolactone hydrochloride (lactone) on C18 solid-phase extraction cartridge creates a problem of insufficient enantiomeric purity (content of L-isomer) of the product. The results of a systematic study of the influence of reaction parameters (lactone/base and the EtOH/H20 ratios, time of 11C-methylation) on the content of L-isomer in the preparation are presented. The developed method of on-line [11C]MET synthesis allows to obtain a product with a sufficiently high radiochemical yield (75 +/- 3%, n = 100, based on [11C]CH3I) and reliably high content of L-isomer (93.7 +/- 0.5%) satisfying the requirements of clinical applications. [11C] MET synthesis was performed on a fully automated module designed by the Institute of Human Brain (IHB RAS).


Subject(s)
Brain Neoplasms/diagnosis , Homocysteine/analogs & derivatives , Methionine/chemical synthesis , Positron-Emission Tomography , Radiopharmaceuticals , Animals , Automation, Laboratory , Brain Neoplasms/pathology , Carbon Radioisotopes/chemistry , Chemical Phenomena , Homocysteine/chemical synthesis , Humans , Methionine/analogs & derivatives , Methylation , Stereoisomerism
2.
Bioorg Khim ; 35(3): 334-43, 2009.
Article in Russian | MEDLINE | ID: mdl-19621048

ABSTRACT

Tyrosine derivatives labeled with a short-living fluorine 18 isotope (T(1/2) 110 min), namely 2-[(18)F]fluoro-L-tyrosine (FTYR) and O-(2'-[(18)F]fluoroethyl)-L-tyrosine (FET), promising radiopharmaceutical products (RPP) for positron emission tomography (PET), were obtained by asymmetric synthesis. Accumulation of FTYR and FET in the rat tumor "35 rat glioma" and in abscesses induced in Vistar mouse muscles was studied and compared with that of a well-known glycolysis radiotracer 2-[(18)F]fluoro-2-deoxy-D-glucose (FDG). It was shown that the relative accumulation indices of amino acid RPP were considerably lower than those of FDG. At the same time, tumor/muscle ratios were high enough (2.9 for FET and 3.9 for FTYR 120 min after injection) for reliable tumor visualization. The data obtained indicated a possibility in principle to use FTYR and FET for differentiated PET diagnostics of brain tumors and inflammation lesions. Of the tyrosine derivatives studied, FET seems to be the most promising agent due to a simple and easily automated method of preparation based on direct nucleophilic substitution of the leaving tosyloxy group of an enantiomerically pure Ni-(S)-BPB-(S)-Tyr(CH2CH2OTs) precursor by an activated [(18)F]fluoride.


Subject(s)
Abscess/diagnostic imaging , Brain Neoplasms/diagnostic imaging , Glioma/diagnostic imaging , Radiopharmaceuticals/chemical synthesis , Tyrosine/analogs & derivatives , Abscess/metabolism , Animals , Brain Neoplasms/metabolism , Fluorine Radioisotopes , Fluorodeoxyglucose F18/pharmacokinetics , Glioma/metabolism , Isotope Labeling , Muscle, Skeletal/diagnostic imaging , Muscle, Skeletal/metabolism , Neoplasm Transplantation , Radionuclide Imaging , Radiopharmaceuticals/pharmacokinetics , Rats , Rats, Wistar , Tissue Distribution , Transplantation, Heterologous , Tyrosine/chemical synthesis , Tyrosine/pharmacokinetics
3.
Appl Radiat Isot ; 67(4): 598-601, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19162492

ABSTRACT

[(18)F]altanserin is the preferred radiotracer for in-vivo labeling of serotonin 2A receptors by positron emission tomography (PET). We report a modified synthesis procedure suited for reliable production of multi-GBq amounts of [(18)F]altanserin useful for application in humans. We introduced thermal heating for drying of [(18)F]fluoride as well as for the reaction instead of microwave heating. We furthermore describe solid phase extraction and HPLC procedures for quantitative determination of [(18)F]altanserin and metabolites in plasma. The time course of arterial plasma activity with and without metabolite correction was determined. 90 min after bolus injection, 38.4% of total plasma activity derived from unchanged [(18)F]altanserin. Statistical comparison of kinetic profiles of [(18)F]altanserin metabolism in plasma samples collected in the course of two ongoing studies employing placebo, the serotonin releaser dexfenfluramine and the hallucinogen psilocybin, revealed the same tracer metabolism. We conclude that metabolite analysis for correction of individual plasma input functions used in tracer modeling is not necessary for [(18)F]altanserin studies involving psilocybin or dexfenfluramine treatment.


Subject(s)
Fluorine Radioisotopes/chemistry , Ketanserin/analogs & derivatives , Chromatography, High Pressure Liquid , Fluorine Radioisotopes/blood , Humans , Ketanserin/blood , Ketanserin/chemical synthesis , Positron-Emission Tomography , Quality Control
4.
Nucl Med Biol ; 31(5): 597-603, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15219278

ABSTRACT

We describe a new method for the asymmetric synthesis of [(18)F]fluorinated aromatic alpha-amino acids (FAA) under phase transfer conditions using achiral glycine derivative NiPBPGly and (S)-NOBIN as a novel substrate/catalyst pair. The key alkylation step proceeds under mild conditions. Substituted [(18)F]fluorobenzylbromides were prepared using nucleophilic [(18)F]fluoride and were used as alkylation agents. Two important FAA, 2-[(18)F]fluoro-L-tyrosine (2-FTYR) and 6-[(18)F]fluoro-L-3,4-dihydroxyphenylalanine (6-FDOPA), were synthesized with an ee of 92 and 96%, respectively. The total synthesis time was 110-120 min and radiochemical yields (d.c.) were 25+/-6% for 2-FTYR and 16+/-5% for 6-FDOPA.


Subject(s)
2-Naphthylamine/analogs & derivatives , 2-Naphthylamine/chemistry , Dihydroxyphenylalanine/analogs & derivatives , Dihydroxyphenylalanine/chemistry , Dihydroxyphenylalanine/pharmacokinetics , Glioma/metabolism , Isotope Labeling/methods , Naphthols/chemistry , Tyrosine/chemistry , Tyrosine/pharmacokinetics , Animals , Catalysis , Dihydroxyphenylalanine/isolation & purification , Fluorine Radioisotopes/chemistry , Fluorine Radioisotopes/isolation & purification , Fluorine Radioisotopes/pharmacokinetics , Glioma/diagnostic imaging , Isomerism , Metabolic Clearance Rate , Organ Specificity , Phase Transition , Radionuclide Imaging , Radiopharmaceuticals/chemical synthesis , Radiopharmaceuticals/isolation & purification , Radiopharmaceuticals/pharmacokinetics , Rats , Rats, Wistar , Tissue Distribution , Tyrosine/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL
...